RetiSpec
Noninvasive Eye Scan to Detect Alzheimer's Disease
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
RetiSpec | 03/07/2021 | Cognitive Assessment & Enhancement | Medical devices | Medical equipment | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Other imaging methods | 01/01/2016 | "1-10" |
RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye. The company's goal is to enable the widespread early detection of Alzheimer's disease through accessible and scalable screening.
Through a quick eye exam, RetiSpec opens a window of opportunity for timely and specific therapeutic interventions so that the progression of the disease can be slowed or even prevented.
The company's patented technology harnesses hyperspectral imagery in synergy with machine learning to allow for rapid, simple, and cost-effective identification of Alzheimer's biomarkers years before the emergence of clinical symptoms. RetiSpec uses computer vision and machine-learning algorithms to detect the unique signatures of Alzheimer's biomarkers in seconds.